Silence Therapeutics says Phase 2 SANRECO trial meets primary endpoint for divesiran in polycythemia vera
SLN•Phase 2 SANRECO trial meets primary endpoint
Silence Therapeutics reported positive topline Phase 2 SANRECO results for divesiran in phlebotomy-dependent polycythemia vera, supporting a best-in-class positioning.
The trial met its main efficacy goal, showing most treated patients maintained hematocrit control without needing phlebotomy versus placebo.
Secondary measures improved and safety was consistent
Secondary measures also improved, including reduced phlebotomy use, better iron markers, and symptom scores.
Safety was consistent with earlier studies, with no new safety signals reported.
Full data will be presented at a future medical congress; Phase 3 development is planned.
